<DOC>
	<DOCNO>NCT00001202</DOCNO>
	<brief_summary>This study continuation two previous study conduct NIH . The first study , `` Treatment True Precocious Puberty Long-Acting Lutenizing Hormone Releasing Hormone Analog ( D-Trp ( 6 ) -Pro ( 9 ) -Net-LHRH ) '' less optimal result . Some patient , diagnose familial isosexual precocious puberty , inadequate response medication observe high level testosterone , advance bone aging , complication disease . As result patient enrol second study In second study , `` Spironolactone Treatment Boys Familial Isosexual Precocious Puberty '' , - patient receive another medication , spironolactone ( Aldactone ) . The drug block effect testosterone , -but bone age advancement improve . Some patient begin experience gynecomastia ( abnormal growth male breast ) . Researchers believe may effect elevate level estrodiol ( form female hormone , estrogen ) . In present study , testolactone add drug regimen block production estrogen . The study therefore use spironolactone prevent action male hormone ( androgen ) testolactone block production female hormone ( estrogen ) . Deslorelin , LHRH analog work turn true ( central ) puberty , add drug regimen true puberty begin . This know boys familial male precocious puberty go true puberty early ( despite treatment spironolactone testolactone ) , happen , spironolactone testolactone longer effective . The goal treatment delay sexual development appropriate age prevent short adult stature ( height ) .</brief_summary>
	<brief_title>Treatment Boys With Precocious Puberty</brief_title>
	<detailed_description>Most male precocious puberty refer NIH successfully treat protocol 79-CH-0112 `` Treatment True Precocious Puberty Long-Acting Luteinizing Hormone Releasing Hormone Analog ( D-Trp6-Pro9-Net-LHRH ) . '' A subset patient , however , familial male isosexual precocity , inadequate response LHRH analog demonstrate high serum testosterone level , rapid advancement bone age , testicular growth , sperm production , lack regression secondary sex characteristic . These patient low baseline gonadotropin level lack pubertal response LHRH , whereas patient respond LHRH analog clear evidence central precocious puberty . As alternative approach treatment , patient familial male precocious puberty enrol protocol 83-CH-0028 , `` Spironolactone Treatment Boys Familial Isosexual Precocious Puberty '' . Spironolactone ( Aldactone ) antiandrogen also reduce testosterone synthesis inhibit enzyme 17-hydroxylase . This treatment decrease plasma testosterone level inhibit peripheral effect testosterone target tissue . This apparent decrease acne frequency spontaneous erection . Bone age advancement , however , slow spironolactone gynecomastia begin occur number patient . Both process may result persist elevate estradiol level . To attempt reduce elevate estrogen level patient normal prepubertal level , plan use testolactone ( Teslac ) inhibit aromatase , last step estrogen biosynthesis . Testolactone previously use similar purpose girl gonadotropin-independent precocious puberty ( McCune-Albright Syndrome ) protocol 82-CH-0165 , `` Testolactone treatment girl LHRH analog-resistant precocious puberty due autonomous non-neoplastic ovarian estrogen secretion . '' We plan administer combine spironolactone testolactone treatment-spironolactone inhibit action androgen , testolactone block formation estrogen . The goal treatment delay sexual maturation prevent early closure epiphyses adult short stature . These goal partially meet spironolactone postulate addition testolactone improve response slow bone growth prevent gynecomastia . Preliminary result use regimen demonstrate blockade androgen action estrogen synthesis effective treatment familial male precocious puberty . Throughout therapy , patient receive frequent clinical , hormonal , toxicological monitoring .</detailed_description>
	<mesh_term>Puberty , Precocious</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Testolactone</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients familial male precocious puberty admit Clinical Center . In order eligible study , follow criterion meet : Boys 10 year age less . Tanner II IV pubertal development . Unfused epiphyses bone film . Evidence precocious puberty secondary another recognize cause pseudopuberty : 1 . We exclude congenital adrenal hyperplasia , document pretreatment androgen level , 1hour ACTH test , include measurement 11deoxycortisol 17OHprogesterone 0 60 minute . 2 . We exclude tumor adrenal testis physical exam , ultrasound , measurement adrenal androgen ( DHA , DHAS , androstenedione ) . Elevated testosterone level measure 10 , 2pm , 10 pm 2 24 hour period .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2004</verification_date>
	<keyword>Luteinizing Hormone</keyword>
	<keyword>High Serum Testosterone Levels</keyword>
	<keyword>Low Baseline Gonadotropin</keyword>
	<keyword>LHRH</keyword>
	<keyword>Precocious Puberty</keyword>
	<keyword>Familial Isosexual Precocious Puberty</keyword>
</DOC>